Lung Cancer Screening for Lung Cancer

(CHAMP Trial)

This trial explores new methods to make lung cancer screening easier and more accessible. It tests the DELFI Diagnostics FirstLook Lung Cancer Screening Blood Test alongside the traditional low-dose CT scan. The goal is to determine if the blood test can simplify the process and increase screening rates. Individuals who have smoked for 20 years or more and either still smoke or quit within the last 15 years might be suitable candidates. Participants can choose between the blood test, a CT scan, or opt out of screening, with follow-up options discussed annually. As an unphased trial, this study offers participants the chance to contribute to innovative research that could transform lung cancer screening for future patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

A previous study found the DELFI Diagnostics FirstLook Lung Cancer Screening Blood Test to be safe and easy to handle. This test involves a simple blood draw to check for DNA changes that might indicate lung cancer. Research has shown that this blood test effectively detects early-stage lung cancer with high accuracy. So far, studies have reported no major side effects or safety issues.

The low-dose CT scan is already a standard method for lung cancer screening and is recommended by the U.S. Preventive Services Task Force. It is generally safe, although some people may worry about radiation exposure. However, the radiation dose is very low, and the benefits of early cancer detection usually outweigh the risks.

Researchers are excited about the DELFI Diagnostics FirstLook Lung Cancer Screening Blood Test because it offers a new, minimally invasive way to detect lung cancer early. Unlike the standard low-dose CT scans that require imaging technology, this blood test analyzes patterns in cell-free DNA fragments using advanced whole-genome sequencing and machine-learning techniques. This method could make lung cancer screening more accessible and less intimidating, as it only requires a simple blood draw. Plus, it complements existing CT scans by helping to identify candidates who might need further imaging, potentially catching cancer sooner.

Studies have shown that the DELFI Diagnostics FirstLook Lung Cancer Screening Blood Test effectively detects lung cancer early. It has an 80% sensitivity, correctly identifying 80% of individuals with lung cancer. Additionally, it boasts a 99.8% negative predictive value, accurately confirming the absence of lung cancer when the test result is negative. This reliability makes it a strong option for early detection. Participants in this trial may opt for the DELFI blood test, which analyzes tiny DNA fragments in the blood using advanced computer techniques to detect cancer signs. This blood test offers a less invasive alternative to traditional screening methods.³⁴⁵⁶⁷